Rolph Timothy's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Apr 10, 2025
- Accession no.
- 0000950170-25-052956
- Filed
- Apr 10, 2025
- Trade date
- Apr 7, 2025
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $224.3K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rolph TimothyCIK 0001779479 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 7, 2025 | Common Stock | MOption exerciseAcquired | +6,250 | $21.10 | +$131,875 | 175,971 | Direct | |
| Apr 7, 2025 | Common Stock | SSaleDisposed | −2,200 | $35.36 | −$77,792 | 173,771 | Direct | |
| Apr 7, 2025 | Common Stock | SSaleDisposed | −3,750 | $36.05 | −$135,187.5 | 170,021 | Direct | |
| Apr 7, 2025 | Common Stock | SSaleDisposed | −100 | $36.93 | −$3,693 | 169,921 | Direct | |
| Apr 7, 2025 | Common Stock | SSaleDisposed | −200 | $37.92 | −$7,584 | 169,721 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 7, 2025 | Common Stock | MOption exerciseDisposed | −6,250 | $0.00 | $0 | 28,718 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.